Lefox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lefox

What is Lefox? The Foundational Identity of Levofloxacin

Property Description
Active ingredient Levofloxacin
Form Tablet, Solution for Infusion
Pharmacological class Fluoroquinolone Antibiotic
Common purpose Elimination of bacterial pathogens
Origin Synthetic (L-isomer of Ofloxacin)

What Type of Medicine is Lefox (Levofloxacin)?

Lefox is a synthetic medicinal product whose active ingredient, Levofloxacin (INN), is classified as a systemic antibiotic. This medicine belongs to the fluoroquinolone class of antibacterials, which are purely chemical agents designed for broad and potent antimicrobial action throughout the body. Levofloxacin is a broad-spectrum antibiotic with activity against a variety of microorganisms. This confirms the medicine’s recognized role in addressing a wide range of bacterial challenges. Lefox is known for being a prescription-only medicine, signifying its intended use for serious systemic infections that require professional medical supervision.

Composition, Origin, and Available Forms

The core of Lefox is the active substance Levofloxacin, which functions as a single-ingredient product. Chemically, Levofloxacin is the purified L-isomer of the older antimicrobial compound, Ofloxacin. This chiral distinction ensures that the finished product contains the most biologically active component. The drug is designated as an antibacterial agent in multiple dosage forms, including the oral tablet and the sterile solution for intravenous infusion. The availability in these two forms allows necessary flexibility for administering the medicine, whether in outpatient or hospital settings.

The General Purpose of this Broad-Spectrum Agent

The general function of Lefox is to achieve the definitive elimination of bacterial pathogens through a bactericidal action. This potent effect stems from the drug's capacity to interfere with the fundamental genetic machinery of the bacterial cell, actively killing the microbes. This broad-spectrum and bactericidal capability represents the intended therapeutic benefit derived from its use as an antimicrobial medicine, such as in typical scenarios requiring treatment for severe respiratory or skin structure infections.

Regulatory References

  1. MedlinePlus Drug Information: Levofloxacin

What side effects are possible with Lefox?

Adverse Reaction Scope

The official labeling for Levofloxacin establishes a safety profile defined by serious, disabling risks and specific restrictions on use. Adverse reactions are formally categorized by the physiological systems they affect, with incidence rates noted in clinical trials.

Category Description
Key adverse reaction categories Disabling and potentially irreversible effects (tendons, nerves, CNS), cardiac risks, and severe gastrointestinal effects.
Frequency classification Common (3%) reactions include nausea, headache, diarrhea, insomnia, constipation, and dizziness.
System-organ classes involved Musculoskeletal, Nervous System, Gastrointestinal, Hepato-Biliary, and Cardiac Disorders are all officially documented as being affected.
Serious adverse reactions Tendinitis and Tendon Rupture; Peripheral Neuropathy; Central Nervous System Effects (e.g., convulsions, anxiety, depression); Hepatotoxicity (severe, sometimes fatal); and Prolongation of the QT interval.
Population-specific safety considerations Older Adults (mathbf>60 years): Increased risk of tendinitis and tendon rupture. Patients on Corticosteroids and Organ Transplant Recipients: Increased risk of tendon disorders. Use is avoided in patients with a history of Myasthenia Gravis.
Dose- or exposure-related patterns Serious effects can have a delayed onset, occurring up to several months after treatment completion. Severe hypersensitivity and certain CNS effects may also occur after the first dose.
Safety-related restrictions or limitations Due to the risk of disabling and potentially irreversible serious adverse reactions, the drug is officially reserved for use in patients who have no alternative treatment options for certain specified infections.

Regulatory Safety Structure (High-Level)

The official safety profile of Levofloxacin is defined by high-level restrictions and specific warnings about its potential to cause disabling, multi-systemic serious adverse reactions. This regulatory structure dictates that the medicine's use is often reserved for specific clinical scenarios where the therapeutic necessity outweighs the documented risks of these serious and sometimes delayed effects. The explicit documentation of risk factors based on age and concomitant drug use provides the formal framework for understanding the medicine's safety characteristics in patient populations.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

If an overdose of this medication is suspected, immediate medical attention is required. Overdose with fluoroquinolone antibiotics, such as Levofloxacin (the likely active ingredient in Lefox), may lead to serious and potentially life-threatening symptoms, particularly affecting the central nervous system and gastrointestinal tract.

Documented Overdose Presentations

Overdose presentations recorded in regulatory documents for this class of medicine often include neurological and digestive system effects. Clinical manifestations may encompass:

  • Central Nervous System (CNS) Effects: Symptoms such as confusion, disorientation, dizziness, drowsiness, slurred speech, tremors, and convulsions (seizures).
  • Gastrointestinal Distress: Severe nausea and vomiting are common signs.
  • Cardiac Risks: The drug may carry a risk of QT interval prolongation, which can lead to irregular heart rhythm.

Required Emergency Actions

Call emergency services immediately if any overdose symptoms or an excessive dose are suspected. Follow the instructions of emergency personnel. Do not attempt to induce vomiting unless directed to do so by a medical professional.

Urgent medical management typically focuses on supportive care, maintaining adequate hydration, and continuous monitoring of the electrocardiogram (ECG) due to the risk of cardiac rhythm changes. Due to its limited metabolism, hemodialysis or peritoneal dialysis is not highly effective in removing the drug from the system. Immediate assessment by a hospital emergency department is essential to manage symptoms and prevent complications.

Therapeutic Uses of Lefox

The active ingredient in Lefox is commonly used in conditions presenting with systemic or localized discomfort. It is an antibacterial prescription medicine approved for the treatment of certain bacterial infections, such as community-acquired pneumonia, acute worsening of chronic bronchitis, anthrax, urinary tract infections, and acute sinus infections.

The medicine is applied across therapeutic domains where additional symptomatic support is needed, including conditions linked to organ-specific functional stress. It is relevant when supportive symptom management is appropriate in scenarios where symptoms cluster into patterns requiring specialized assistance. This medicine is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed.

Key Symptom Domains and Benefits

Lefox plays a role in managing symptoms that create noticeable physiological strain, such as painful urination (dysuria), high fever and chills, and localized swelling and redness at the infection site. It provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during acute episodes. It assists with maintaining functional stability in conditions characterized by periods of heightened symptoms.


Quick Fact: Relevant for Easing Acute Symptoms The medicine is commonly used for conditions that present with acute or disruptive episodes, helping to ease the overall symptom load associated with conditions marked by increased physiological stress.

Eligibility and Restrictions for Use

Lefox is contraindicated and must not be used in several patient populations according to official regulatory labeling. Absolute non-eligibility applies to individuals with known hypersensitivity to levofloxacin or any other quinolone, and patients with a history of epilepsy or tendon disorders related to previous fluoroquinolone exposure. Use is also formally prohibited during pregnancy and breastfeeding.

The medicine is generally contraindicated in children and growing adolescents for standard indications. In the United States, pediatric use is highly restricted and permitted only for serious infections like Inhalational Anthrax and Plague in patients ge 6 months of age.

Conditional use and restrictions apply to several other patient groups. Patients with impaired renal function require a mandatory regulatory dosage adjustment. Use should be avoided in those with a history of Myasthenia Gravis due to the risk of muscle weakness exacerbation. Caution is required for elderly patients and individuals with risk factors for QTc interval prolongation, seizures, or blood sugar disturbances, such as diabetes. Additionally, regulatory agencies advise reserving this medicine for certain uncomplicated infections only when alternative treatment options are unavailable.

What should I know about interactions with other medicines?

Lefox Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Lefox (Levofloxacin) based on chelation, altered clearance, and pharmacodynamic effects.

Products Requiring Timing Separation

The absorption of oral Levofloxacin is significantly decreased when co-administered with products containing multivalent cations (e.g., magnesium, aluminum, iron, zinc) due to a binding process known as chelation. This requires that oral Levofloxacin formulations must be taken at least two hours before or two hours after the intake of these products, including antacids, Sucralfate, and mineral supplements.

Pharmacodynamic and Clearance Interactions

Interacting Product Category Officially Documented Effect
Vitamin K Antagonists (e.g., Warfarin) Enhanced anticoagulant effect, requiring coagulation test monitoring.
Theophylline or NSAIDs (e.g., Fenbufen) May result in a pronounced lowering of the cerebral seizure threshold.
Probenecid or Cimetidine Reduces Levofloxacin renal clearance, leading to increased exposure of Levofloxacin.
Drugs Prolonging QT Interval Co-administration should be avoided due to the potential for an additive effect on the QT interval.
Corticosteroids Increased risk of tendinopathy, particularly noted in geriatric patients.

These official statements define requirements for co-administering Levofloxacin with other products, necessitating close monitoring or dose spacing where applicable.

Mechanism of Action

How Lefox Works: Mechanism of Action

Targeting the Essential Genetic Machinery of Bacteria

The function of Lefox is to directly interfere with the core biological processes required for bacterial survival and proliferation. The drug acts as an inhibitor of two non-human enzymes: DNA Gyrase and Topoisomerase IV. These bacterial enzymes are vital for uncoiling and separating the genetic material, allowing for accurate DNA replication and cell division. Lefox stabilizes the transient enzyme-DNA complex after the DNA has been cleaved, effectively locking the bacterial chromosome in a broken state.

Inducing Lethal Double-Stranded DNA Breaks

The molecular blockade of these essential enzymes leads to the rapid, widespread accumulation of double-stranded DNA breaks within the pathogen's genome. This massive, irreparable genetic damage triggers the bacterial cell's internal distress and self-destruction signals, resulting in a swift bactericidal effect. The physiological consequence of this targeted action is the systematic killing (lysis) of susceptible bacterial pathogens.

Constraints on Mechanism Efficacy

The drug's mechanism relies on achieving a sufficient concentration at the target enzymes. Its function can be limited by bacterial resistance mechanisms, such as genetic mutations in the DNA Gyrase or Topoisomerase IV genes that reduce binding affinity, or by bacterial efflux pumps that actively expel the Levofloxacin molecule from the cytoplasm, preventing the lethal DNA damage cascade.

Dosage and Administration Information

How to Use Lefox: Official Administration Guidelines

Lefox (Levofloxacin) is used according to specific, standardized instructions to ensure correct administration. The medicine is available for both oral administration as tablets or an oral solution, and for intravenous (IV) administration as a solution for infusion. The selection between the two routes often facilitates a switch from initial IV treatment to oral therapy, known as sequential therapy, which typically utilizes the same dosage.

The standard frequency for adult dosing across all approved indications is once daily (every 24 hours). Doses range from 250 mg to 750 mg per day, with the required treatment duration ranging from short courses of 3 days up to 60 days, depending on the specific condition.

Administration Conditions and Adjustments

Proper use of Lefox requires adherence to certain time-relationship and procedural constraints. Oral tablets may be taken with or without food. However, the oral solution is recommended to be taken 1 hour before or 2 hours after eating. Crucially, all oral forms must be administered at least two hours before or two hours after ingesting products containing multivalent cations (e.g., iron or magnesium salts), as these substances can interfere with the drug’s absorption.

Dosing requires adjustment for specific populations. A mandatory dose adjustment is required for adult patients with renal impairment (Creatinine Clearance < 50 mL/min), which may involve reducing the dose and/or extending the interval to every 48 hours. In contrast, no dose adjustment is generally required for patients with hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Lefox


Evidence from Trials for Respiratory and Sinus Infections

The research examining the evaluation of Lefox for certain respiratory and sinus conditions primarily consists of Randomized Controlled Trials (RCTs). These studies typically compare the medicine to other active antimicrobial agents studied in trials rather than against an inactive substance. Researchers focus on short-term outcomes, using defined time intervals to see how symptoms evolved in the observed populations.

Studies for Community-Acquired Pneumonia (CAP)

Research has explored Lefox in both adults and specific pediatric populations with Community-Acquired Pneumonia. These trials were designed to examine outcomes related to physical discomfort and systemic or functional imbalance. Researchers monitored endpoints such as the time needed for patients to achieve clinical stability and the rate at which the targeted bacteria were cleared, known as microbiologic eradication. Trials reported measurements of clinical status and microbiologic eradication that were documented across the groups studied receiving active agents. The evidence relies heavily on non-inferiority trials comparing Lefox to an active drug, as opposed to trials assessing its standalone evaluation against an inactive substance.

Studies for Acute Bacterial Sinusitis (ABS) and Chronic Bronchitis

For conditions like Acute Exacerbation of Chronic Bronchitis (AECB) and Acute Bacterial Sinusitis (ABS), studies monitored the evaluation of short treatment courses, typically comparing different durations or different antimicrobial medicines. Findings across studies described patterns of symptom evolution that were documented in the trial groups receiving active agents. Official guidance often notes that, for these less severe infections, the evaluation of this antibiotic class is generally reserved for patients who have limited alternative treatment options.


Evidence from Trials for Urinary Tract and Prostate Infections

Research for urinary and prostate infections has used active-controlled trials to explore the medicine's evaluation in conditions characterized by fluctuating or episodic manifestations linked to inflammatory or irritative states. For Complicated Urinary Tract Infections (cUTI), research has examined short-course treatment regimens, monitoring outcomes such as changes in fever and painful urination. For Chronic Bacterial Prostatitis, longer treatment duration studies tracked the pattern of sustained absence of infection following treatment completion. Studies reported clinical and bacteriologic outcomes that were documented across the various antimicrobial treatment groups studied. Limitations include the need for ongoing surveillance, as rising patterns of microbial resistance introduce uncertainty about the sustained applicability of older trial findings.

Key Studies & References A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis

Frequently Asked Questions (FAQ)

Common questions about Lefox (FAQ)


Q: Is Lefox the same type of medicine as [similar drug name]?

A: Lefox (Levofloxacin) is classified as a fluoroquinolone antibiotic. While other medicines in this class, such as Ciprofloxacin, share a similar mechanism of action, official documents describe Levofloxacin as the L-isomer of Ofloxacin. Studies and official information indicate that the drug is described in official documents as being effective against a range of bacteria, including those causing pneumonia, and is typically dosed once daily.


Q: How quickly does Lefox start to work after taking it?

A: According to official pharmacokinetic data, Levofloxacin typically reaches its peak concentration in the bloodstream approximately one to two hours after an oral dose. This concentration indicates when the drug is circulating in the body and available to address the target bacteria.


Q: How long does the effect of one dose of Lefox last?

A: The drug’s activity is related to how quickly it is eliminated from the body. Official pharmacokinetic data describes the mean terminal elimination half-life of Levofloxacin as ranging from approximately six to eight hours in patients with normal kidney function.


Q: Can Lefox cause tiredness or drowsiness?

A: Official regulatory documents list dizziness and insomnia (trouble sleeping) as common reported reactions. Drowsiness (somnolence) is also described as an uncommon adverse effect (affecting up to 1 in 100 people). Severe tiredness is noted as a symptom that may be associated with a serious adverse reaction, such as hepatotoxicity, and warrants immediate medical attention.


Q: Are there any common foods or drinks to avoid while taking Lefox?

A: While the oral tablets may be taken without regard to food, they must be separated from products containing multivalent cations by at least two hours. Common food products like milk, yogurt, or calcium-fortified juice contain these metal ions. Official regulatory information describes that these products must be avoided during the timing window to help prevent reduced absorption.


Q: Is it necessary to take Lefox at the exact same time every day?

A: The medicine is prescribed for once-daily dosing, which is every 24 hours. Regulatory guidance recommends taking the dose at about the same time each day to maintain consistent drug levels. The official instructions for a missed dose suggest that precise, minute-to-minute timing is not the primary factor, but rather consistency in the 24-hour cycle.


Q: If I miss a dose of Lefox, what is the usual recommendation?

A: The general guidance in regulatory documents is to take the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. The regulatory guidance is to resume the regular schedule. Official instructions specify that two doses should not be taken to compensate for a missed dose.


Q: Does Lefox have a risk of addiction or dependence?

A: Addiction or physical dependence is not listed as a documented risk in official regulatory materials. However, the medicine has been associated with serious central nervous system (CNS) effects such as anxiety, depression, and psychotic-like behaviors.


Q: Is it true that Lefox can affect blood pressure?

A: While changes in blood pressure are not listed as a common effect, the regulatory profile includes dizziness and lightheadedness as common reactions. These effects are officially noted as potentially being related to changes in the nervous system or, in some cases, to low blood pressure (hypotension).


Q: How long do most patients typically stay on Lefox therapy?

A: The total duration of treatment is based on the specific infection being treated and can range from 3 to 60 days. For many common infections, clinical trial data and guidelines often reference short courses, with a typical duration of 5 to 14 days.


Q: Do studies show that Lefox is generally well-tolerated?

A: Official clinical trial data provides frequency information for specific adverse reactions. These reports indicate a generally low rate of treatment discontinuation due to adverse events (typically around 3–4% in studies), which gives an indication of the medicine's tolerability profile in the studied populations.


Q: Is Lefox considered a long-term treatment option?

A: The medicine is generally prescribed for a specific, defined course of treatment, with a maximum duration of up to 60 days for rare indications. Due to the risk of serious, potentially irreversible side effects, official warnings stress that the drug should not generally exceed the required treatment duration.


Q: What should I do if I feel like Lefox isn't working for me anymore?

A: Official instructions specify that the full prescribed course must be completed to ensure the bacteria are fully eliminated. However, if symptoms worsen or do not start to get better, official regulatory guidance states that the healthcare provider should be informed immediately.


Q: Does Lefox need to be stopped gradually, or can I stop suddenly?

A: The medicine must be stopped immediately at the first sign of a serious adverse reaction, such as tendon pain, nerve pain, or severe tiredness. In this case, a healthcare professional should be contacted right away. In all other cases, the official instruction is to not stop taking the medicine until the full prescribed course is completed.


Q: What should I know about driving or operating machinery while on Lefox?

A: Official regulatory information describes that patients should refrain from driving, operating machinery, or participating in activities that require mental alertness or coordination until they know how the medication affects them. This warning is due to the potential for side effects like dizziness, lightheadedness, and visual disturbances.


Q: Are there specific symptoms that require immediate medical attention while taking Lefox?

A: Yes. Official warnings describe several signs and symptoms that warrant immediate reporting to a healthcare provider. These include signs of a severe allergic reaction, tendon pain or swelling, new or worsening nerve pain (numbness, tingling), severe headache, or symptoms associated with severe liver damage (jaundice, dark urine).


Q: Do certain groups of people have a higher chance of side effects from Lefox?

A: Yes. Official regulatory documents define populations with an increased risk of certain serious side effects. The risk of tendon injury is increased in older adults (over 60 years of age), patients who are also taking corticosteroids, and those who have received an organ transplant.


Q: Can I take other supplements or vitamins along with Lefox?

A: The drug's absorption may be substantially reduced if taken at the same time as mineral-containing products like multivitamin preparations with zinc or supplements with iron. These products require a timing separation of at least two hours before or two hours after the Levofloxacin dose. Official labeling does not mandate timing restrictions for non-mineral vitamins.


Q: What are the criteria that determine if someone is eligible to use Lefox?

A: Official regulatory criteria state that the drug should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Furthermore, due to the risk of disabling adverse reactions, the drug is officially reserved for use for certain specified infections only when alternative treatment options are not available.


Q: Is there a risk of withdrawal symptoms if Lefox is stopped?

A: The official safety profile does not list a common or expected withdrawal syndrome from stopping the drug. However, the medicine is associated with serious adverse effects on the central nervous system (CNS), and symptoms like anxiety, depression, and memory impairment have been reported to occur after discontinuation.


Q: Does Lefox cause weight changes?

A: Weight change is not listed as a common side effect in the official regulatory documents (those occurring in at least 1 in 100 people). While some official patient information notes loss of appetite as a possible side effect, significant weight changes are not a listed frequent adverse reaction.


Q: What is the typical timeframe for a doctor to review treatment with Lefox?

A: Official regulatory documents do not specify a universal timeframe for review, but they require that the treating physician ensures the drug is used for the shortest duration necessary. Monitoring of certain factors, such as coagulation tests for patients on Warfarin or blood glucose for patients on anti-diabetic agents, is officially recommended to be closely monitored.


Q: What is the difference between an adverse event and a side effect of Lefox?

A: The terminology in official sources describes different categories of undesirable effects. An adverse event is broadly defined as any unwanted medical occurrence that happens after the medicine is taken, regardless of whether the drug caused it. A side effect is an adverse event for which a clear cause-and-effect relationship with the medicine is strongly suspected or proven.


Q: Is Lefox a branded drug or a generic name?

A: The name Levofloxacin is the active ingredient and the internationally accepted generic name. Lefox is one of several brand names under which the medicine containing Levofloxacin is marketed.


Q: Is Lefox used to prevent a condition, or only to treat it?

A: The drug is approved and used to treat a variety of existing bacterial infections. It is also officially approved for the prevention of disease progression following documented exposure to certain specific pathogens, such as Bacillus anthracis (Inhalational Anthrax).


Q: Are mood changes a possible reported side effect of Lefox?

A: Yes. Official regulatory documents list specific psychiatric adverse reactions including anxiety, depression, confusion, and restlessness (agitation). These are part of the serious central nervous system effects that can be associated with the drug.


Q: Does the dosage of Lefox depend on a person's weight?

A: For adult use, the dosage is based on the type and severity of the infection and the patient's kidney function, not their weight. Weight-based dosing is, however, officially used in the pediatric population for the treatment of certain highly specific, serious infections.


Q: Can anxiety or nervousness be a side effect of Lefox?

A: Yes. Anxiety is listed in official documents as a serious adverse reaction that is part of the central nervous system effects associated with the medicine. Nervousness has also been reported as an uncommon adverse effect (up to 1 in 100 people).


Q: Is the purpose of Lefox to treat symptoms or the underlying cause?

A: The official mechanism of action is described as bactericidal, meaning its function is the elimination of bacterial pathogens (the underlying cause of the infection). The subsequent relief of symptoms is an expected outcome that results from the successful clearing of the bacterial infection.


Q: Can Lefox be crushed or split, or must it be swallowed whole?

A: Official regulatory materials state that Levofloxacin tablets should not be crushed and are generally recommended to be swallowed whole. This is primarily due to risks of reduced efficacy and potential administration issues.

How should Lefox be stored and disposed of?

Storage Requirements

Lefox (levofloxacin) tablets and oral solution must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The intravenous injection must be protected from light and it is a requirement to not freeze the product. The injection premix should be stored in its outer foil overwrap until use to maintain product integrity. All formulations must be kept out of the reach of children.

Disposal Instructions

Official guidelines state that unused or expired medicine should generally not be flushed down the toilet or thrown into household waste without following a specific procedure. If a drug take-back program is unavailable, the medicine should be removed from its original container, mixed with an undesirable substance (such as dirt or used coffee grounds), and placed in a sealed container before disposal in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lefox found in:

A-Z Index: